Efficacy and safety of venetoclax-based regimens for the treatment of relapsed/refractory multiple myeloma: a systemic review and meta-analysis

BACKGROUND: Patients with relapsed/refractory multiple myeloma (RRMM) usually have dismal prognostic outcomes. Venetoclax, a selective inhibitor of antiapoptotic protein B-cell lymphoma-2 (BCL-2), demonstrates antimyeloma activity in plasma cells with t(11;14) or high BCL-2 expression. OBJECTIVES: T...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Linchun, Lin, Shaoze, Xing, Xueyang, Su, Yongzhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989383/
https://www.ncbi.nlm.nih.gov/pubmed/36895915
http://dx.doi.org/10.1177/20406207231155028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989383/
https://www.ncbi.nlm.nih.gov/pubmed/36895915
http://dx.doi.org/10.1177/20406207231155028

Ejemplares similares